KIDS Overview

New Product Launches: OrthoPediatrics Corp. has expanded its OrthoPediatrics Specialty Bracing portfolio with the introduction of the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, aimed at treating Developmental Dysplasia of the Hip (DDH) in children aged three years and younger.

Collaboration with Experts: The new products were developed in collaboration with leading pediatric hip specialists, enhancing treatment options for patients and their families.

Commitment to Pediatric Care: Joe Hauser, President of the Specialty Bracing division, emphasized the company's focus on organic product development and its commitment to improving pediatric orthopedic care through innovative solutions.

Comprehensive Product Offering: Founded in 2006, OrthoPediatrics markets over 85 products across various pediatric orthopedic categories, including trauma, deformity, scoliosis, and sports medicine, serving both the U.S. and international markets.

Analyst Price Target Changes: OrthoPediatrics' consensus analyst price target has been lowered from $26.29 to $24.14, reflecting a cautious outlook amid mixed research commentary and short-term challenges.

Bullish Analyst Sentiment: Despite the lowered price targets, several firms maintain positive ratings, emphasizing confidence in the company's core business and long-term prospects, particularly in high-margin product lines.

Bearish Analyst Concerns: Some analysts express caution, citing near-term headwinds and lower guidance, with notable reductions in price targets and concerns over revenue visibility impacting future growth expectations.

Company Developments: OrthoPediatrics announced an intangible asset impairment of $2.27 million, received FDA approval for a new system, and revised its 2025 revenue guidance downward, while also reporting improved net profit margins.

Analyst Ratings Overview: OrthoPediatrics has received mixed ratings from analysts, with 6 bullish, 3 somewhat bullish, and no bearish ratings in the last 30 days, reflecting a shift in sentiment compared to previous months.

Price Target Adjustments: Analysts have lowered their 12-month price targets for OrthoPediatrics, with an average target now at $27.44, down from $36.44, indicating a decrease in expected stock performance.

Financial Performance Metrics: The company has shown a revenue growth rate of approximately 15.68% and maintains a net margin of -11.64%, outperforming industry standards in terms of financial performance.

Debt Management and Ratios: OrthoPediatrics has a debt-to-equity ratio of 0.27, which is below industry norms, suggesting a solid financial structure and effective management of shareholder equity.

Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.

Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.

Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

Genenta Science S.p.A. Update: After a significant drop in regular trading due to a $15 million capital raise announcement, Genenta's shares saw a modest recovery in after-hours trading, indicating potential stabilization as investors assess the long-term impact of the company's strategic collaborations.

EDAP TMS S.A. Recovery: Despite a sharp decline during the day, EDAP's stock rebounded in after-hours trading, reflecting renewed speculative interest, particularly ahead of upcoming investor meetings at the UBS Global Healthcare Conference.

BridgeBio Pharma Inc. Anticipation: BridgeBio's shares rose significantly after hours, driven by investor optimism regarding the upcoming Phase 3 trial results for ADH1, with topline data expected to be released soon.

OrthoPediatrics Corp. Financial Performance: Following the release of its Q3 financial results, OrthoPediatrics experienced a surge in after-hours trading, buoyed by revenue growth and FDA approvals, leading to an optimistic revision of its full-year revenue guidance.